Molecular pathogenesis of endometrial and ovarian cancer

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 287-305

  Merritt, Melissa A ^a   Cramer, Daniel W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

clear cell; Cortical inclusion cysts; Endometrial cancer; Endometrial intraepithelial neoplasia; endometrioid; epidemiology; Fallopian tube; KRAS; mucinous; mullerian; Ovarian cancer; p53; Precursor lesions; PTEN; risk factors; serous; Type I; Type II

Indexed keywords

B RAF KINASE; BETA CATENIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN E; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; ORAL CONTRACEPTIVE AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MUTL; PROTEIN P53;

AGE DISTRIBUTION; ARTICLE; BODY MASS; BREAST FEEDING; CANCER GRADING; CANCER INCIDENCE; CANCER STAGING; CHROMOSOMAL INSTABILITY; CLEAR CELL CARCINOMA; COWDEN SYNDROME; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MICROSATELLITE INSTABILITY; OVARIAN CLEAR CELL CARCINOMA; OVARY CANCER; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SEROUS OVARIAN CARCINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE TUBE;

ANIMALS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 82955214537     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0167     Document Type: Article

References (199)

1. American Cancer Society, Cancer Facts and Figures, 2008.
2. F. Parazzini, S. Franceschi, C. La Vecchia andM. Fasoli, The epidemiology of ovarian cancer, Gynecol Oncol 43 (1991), 9-23.
3. F. Parazzini, C. La Vecchia, L. Bocciolone and S. Franceschi, The epidemiology of endometrial cancer, Gynecol Oncol 41 (1991), 1-16.
4. R. L. Prentice, C. A. Thomson, B. Caan, F. A. Hubbell, G. L. Anderson, S. A. Beresford, M. Pettinger, D. S. Lane, L. Lessin, S. Yasmeen, B. Singh, J. Khandekar, J. M. Shikany, S. Satterfield and R. T. Chlebowski, Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial, J Natl Cancer Inst 99 (2007), 1534-1543.
5. C. P. McPherson, T. A. Sellers, J. D. Potter, R. M. Bostick and A. R. Folsom, Reproductive factors and risk of endometrial cancer, The Iowa Women's Health Study, Am J Epidemiol 143 (1996), 1195-1202.
6. M. F. Fathalla, Incessant ovulation-a factor in ovarian neoplasia? Lancet 2 (1971), 163.
7. Y. Lee, A. Miron, R. Drapkin, M. R. Nucci, F. Medeiros, A. Saleemuddin, J. Garber, C. Birch, H. Mou, R. W. Gordon, D. W. Cramer, F. D. McKeon and C. P, Crum, A candidate precursor to serous carcinoma that originates in the distal fallopian tube, J Pathol 211 (2007), 26-35.
8. A. K. Folkins, E. A. Jarboe, A. Saleemuddin, Y. Lee, M. J. Callahan, R. Drapkin, J. E. Garber, M. G. Muto, S. Tworoger and C. P. Crum, A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations, Gynecol Oncol 109 (2008), 168-173.
9. J. M. Schildkraut, E. Bastos and A. Berchuck, Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer, J Natl Cancer Inst 89 (1997), 932-938.
10. J. Cairns,Mutation and cancer: the antecedents to our studies of adaptive mutation, Genetics 148 (1998), 1433-1440.
11. S. H. Moolgavkar and A. G. Knudson, Jr. , Mutation and cancer: a model for human carcinogenesis, J Natl Cancer Inst 66 (1981), 1037-1052.
12. E. R. Fearon andB. Vogelstein, Ageneticmodel for colorectal tumorigenesis, Cell 61 (1990), 759-767.
13. G. L. Mutter, T. A. Ince, J. P. Baak, G. A. Kust, X. P. Zhou and C. Eng, Molecular identification of latent precancers in histologically normal endometrium, Cancer Res 61 (2001), 4311-4314.
14. E. E. Calle and R. Kaaks, Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms, Nat Rev Cancer 4 (2004), 579-591.
15. M. F. Leitzmann, C. Koebnick, K. N. Danforth, L. A. Brinton, S. C. Moore, A. R. Hollenbeck, A. Schatzkin and J. V. Lacey, Jr. , Body mass index and risk of ovarian cancer, Cancer 115 (2009), 812-822.
16. M. F. Schouten, C. Rivera, D. J. Hunter, D. Spiegelman, H. O. Adami, A. Arslan, W. L. Beeson, P. A. van den Brandt, J. E. Buring, A. R. Folsom, G. E. Fraser, J. L. Freudenheim, R. A. Goldbohm, S. E. Hankinson, J. V. Lacey, Jr. , M. Leitzmann, A. Lukanova, J. R. Marshall, A. B. Miller, A. V. Patel, C. Rodriguez, T. E. Rohan, J. A. Ross, A. Wolk, S. M. Zhang and S. A. Smith-Warner, Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies, Cancer Epidemiol Biomarkers Prev 17 (2008), 902-912.
17. L. G. Escobedo, N. C. Lee, H. B. Peterson and P. A. Wingo, Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women, Obstet Gynecol 77 (1991), 124-128.
18. J. M. Schildkraut, P. J. Schwingl, E. Bastos, A. Evanoff and C. Hughes, Epithelial ovarian cancer risk among women with polycystic ovary syndrome, Obstet Gynecol 88 (1996), 554-559.
19. S. Wild, T. Pierpoint, H. Jacobs and P. McKeigue, Longterm consequences of polycystic ovary syndrome: results of a 31 year follow-up study, Hum Fertil (Camb) 3 (2000), 101-105.
20. M. Sogaard, S. K. Kjaer and S. Gayther, Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention, Acta Obstet Gynecol Scand 85 (2006), 93-105.
21. M. E. Beiner, A. Finch, B. Rosen, J. Lubinski, P. Moller, P. Ghadirian, H. T. Lynch, E. Friedman, P. Sun and S. A. Narod, The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study, Gynecol Oncol 104 (2007), 7-10.
22. S. Malander, E. Rambech, U. Kristoffersson, B. Halvarsson, M. Ridderheim, A. Borg and M. Nilbert, The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer, Gynecol Oncol 101 (2006), 238-243.
23. H. K. Lu and R. R. Broaddus, Gynecologic Cancers in Lynch Syndrome/HNPCC, Fam Cancer 4 (2005), 249-254.
24. S. Uppal, D. Mistry and A. P. Coatesworth, Cowden disease: a review, Int J Clin Pract 61 (2007), 645-652.
25. C. Eng, Will the real Cowden syndrome please stand up: revised diagnostic criteria, J MedGenet 37 (2000), 828-830.
26. C. Black, F. Bogomolniy, M. E. Robson, K. Offit, R. R. Barakat and J. Boyd, Evaluation of germline PTENmutations in endometrial cancer patients, Gynecol Oncol 96 (2005), 21-24.
27. R. M. Beining, L. K. Dennis, E. M. Smith and A. Dokras, Meta-analysis of intrauterine device use and risk of endometrial cancer, Ann Epidemiol 18 (2008), 492-499.
28. K. M. Curtis, P. A. Marchbanks and H. B. Peterson, Neoplasia with use of intrauterine devices, Contraception 75 (2007), S60-S69.
29. R. B. Ness, J. A. Grisso, R. Vergona, J. Klapper, M. Morgan and J. E. Wheeler, Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer, Epidemiology 12 (2001), 307-312.
30. S. S. Tworoger, K. M. Fairfield, G. A. Colditz, B. A. Rosner and S. E. Hankinson, Association of Oral Contraceptive Use, Other Contraceptive Methods, and Infertility with Ovarian Cancer Risk, Am J Epidemiol (2007).
31. X. Castellsague, W. D. Thompsonand R. Dubrow, Tubal sterilization and the risk of endometrial cancer, Int J Cancer 65 (1996), 607-612.
32. A. Green, D. Purdie, C. Bain, V. Siskind, P. Russell, M. Quinn and B. Ward, Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer, Int J Cancer 71 (1997), 948-951.
33. J. V. Lacey, Jr. , L. A. Brinton, R. Mortel, M. L. Berman, G. D. Wilbanks, L. B. Twiggs and R. J. Barrett, Tubal sterilization and risk of cancer of the endometrium, Gynecol Oncol 79 (2000), 482-484.
34. K. Rosenblatt and D. Thomas, Association between tubal ligation and endometrial cancer, Int J Cancer 71 (1997), 129-130.
35. P. D. Terry, T. E. Rohan, S. Franceschi and E. Weiderpass, Cigarette smoking and the risk of endometrial cancer, Lancet Oncol 3 (2002), 470-480.
36. S. J. Jordan, D. C. Whiteman, D. M. Purdie, A. C. Green and P. M. Webb, Does smoking increase risk of ovarian cancer? A systematic review, Gynecol Oncol 103 (2006), 1122-1129.
37. D. W. Cramer, R. F. Liberman, L. Titus-Ernstoff,W. R. Welch, E. R. Greenberg, J. A. Baron and B. L. Harlow, Genital talcexposure and risk of ovarian cancer, Int J Cancer 81 (1999), 351-356.
38. A. J. Gross and P. H. Berg, A meta-analytical approach examining the potential relationship between talc exposure and ovarian cancer, J Expo Anal Environ Epidemiol 5 (1995), 181-195.
39. M. Huncharek, J. F. Geschwind and B. Kupelnick, Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies, Anticancer Res 23 (2003), 1955-1960.
40. M. A. Merritt, A. C. Green, C. M. Nagle and P. M. Webb, Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer, Int J Cancer 122 (2007), 170-176.
41. J. V. Bokhman, Two pathogenetic types of endometrial carcinoma, Gynecol Oncol 15 (1983), 10-17.
42. L. Deligdisch and C. F. Holinka, Endometrial carcinoma: two diseases? Cancer Detect Prev 10 (1987), 237-246.
43. G. L. Mutter, Endometrial carcinogenesis: an integrated molecular, histologic, and functional model of a dualistic disease, in: Molecular Pathology of Gynecologic Cancers, A. Giordano, A. Bovicelli and R. J. Kurman, eds, Springer, 2006.
44. M. E. Sherman, Theories of endometrial carcinogenesis: a multidisciplinary approach, Mod Pathol 13 (2000), 295-308.
45. M. E. Sherman, S. Sturgeon, L. Brinton and R. J. Kurman, Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis, J Cell Biochem Suppl 23 (1995), 160-164.
46. J. B. Basil, P. J. Goodfellow, J. S. Rader, D. G. Mutch and T. J. Herzog, Clinical significance of microsatellite instability in endometrial carcinoma, Cancer 89 (2000), 1758-1764.
47. W. C. Faquin, J. T. Fitzgerald, M. C. Lin, K. A. Boynton, M. G. Muto and G. L. Mutter, Sporadic microsatellite instability is specific to neoplastic and preneoplastic endometrial tissues, Am J Clin Pathol 113 (2000), 576-582.
48. C. A. Hamilton, M. K. Cheung, K. Osann, L. Chen, N. N. Teng, T. A. Longacre, M. A. Powell, M. R. Hendrickson, D. S. Kapp and J. K. Chan, Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers, Br J Cancer 94 (2006), 642-646.
49. M. Hendrickson, J. Ross, P. Eifel, A. Martinez and R. Kempson, Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma, Am J Surg Pathol 6 (1982), 93-108.
50. R. Scully, Tumors of the Ovary and Maldeveloped Gonads, Vol. Second Series,Washington, DC: Armed Forces Institute of Pathology, 1979.
51. O. Ioffe, A. Simsir and S. Silverberg, Pathology, in: Practical Gynecologic Oncology, J. Berek and N. Hacker, eds, Lippincott Williams & Wilkins, 2005.
52. P. Russell, Surface epithelial-stromal tumors of the ovary, in: Blaustein's Pathology of the Female Genital Tract, R. J. Kurman, ed. , Springer-Verlag, New York, 1994, pp. 705- 782.
53. L. Shih and R. Kurman, Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis, Am J Pathol 164 (2004), 1511-1518.
54. G. Singer, R. J. Kurman, H. W. Chang, S. K. Cho and M. Shih Ie, Diverse tumorigenic pathways in ovarian serous carcinoma, Am J Pathol 160 (2002), 1223-1228.
55. C. Lengauer, K. W. Kinzler and B. Vogelstein, Genetic instabilities in human cancers, Nature 396 (1998), 643-649.
56. M. Perucho, Cancer of the microsatellite mutator phenotype, Biol Chem 377 (1996), 675-684.
57. M. Esteller, R. Levine, S. B. Baylin, L. H. Ellenson and J. G. Herman, MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas, Oncogene 17 (1998), 2413-2417.
58. R. J. Steele, A. M. Thompson, P. A. Hall and D. P. Lane, The p53 tumour suppressor gene, Br J Surg 85 (1998), 1460-1467.
59. B. Vogelstein, D. Lane and A. J. Levine, Surfing the p53 network, Nature 408 (2000), 307-310.
60. D. B. Woods and K. H. Vousden, Regulation of p53 function, Exp Cell Res 264 (2001), 56-66.
61. C. J. Sherr, Cancer cell cycles, Science 274 (1996), 1672-1677.
62. C. Tsatsanis and D. A. Spandidos, The role of oncogenic kinases in human cancer (Review), Int J Mol Med 5 (2000), 583-590.
63. A. A. Adjei, Blocking oncogenic Ras signaling for cancer therapy, J Natl Cancer Inst 93 (2001), 1062-1074.
64. G. Pearson, F. Robinson, T. Beers Gibson, B. E. Xu, M. Karandikar, K. Berman, and M. H. Cobb, Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions, Endocr Rev 22 (2001), 153-183.
65. A. S. Dhillon, S. Hagan, O. Rath and W. Kolch, MAP kinase signalling pathways in cancer, Oncogene 26 (2007), 3279-3290.
66. C. Peyssonnaux and A. Eychene, The Raf/MEK/ERK pathway: new concepts of activation, Biol Cell 93 (2001), 53-62.
67. J. I. Risinger, A. K. Hayes, A. Berchuck and J. C. Barrett, PTEN/MMAC1 mutations in endometrial cancers, Cancer Res 57 (1997), 4736-4738.
68. D. Kong, A. Suzuki, T. T. Zou, A. Sakurada, L. W. Kemp, S. Wakatsuki, T. Yokoyama, H. Yamakawa, T. Furukawa, M. Sato, N. Ohuchi, S. Sato, J. Yin, S. Wang, J. M. Abraham, R. F. Souza, K. N. Smolinski, S. J. Meltzer and A. Horii, PTEN1 is frequently mutated in primary endometrial carcinomas, Nat Genet 17 (1997), 143-144.
69. G. L. Mutter, Pten, a protean tumor suppressor, Am J Pathol 158 (2001), 1895-1898.
70. T. Fukuchi, M. Sakamoto, H. Tsuda, K. Maruyama, S. Nozawa and S. Hirohashi, Beta-catenin mutation in carcinoma of the uterine endometrium, Cancer Res 58 (1998), 3526-3528.
71. P. W. Schlosshauer, E. C. Pirog, R. L. Levine and L. H. Ellenson, Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma, Mod Pathol 13 (2000), 1066-1071.
72. G. Moreno-Bueno, C. Gamallo, L. Perez-Gallego, J. C. de Mora, A. Suarez and J. Palacios, beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas, Diagn Mol Pathol 10 (2001), 116-122.
73. R. Wu, Y. Zhai, E. R. Fearon and K. R. Cho, Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas, Cancer Res 61 (2001), 8247-8255.
74. R. T. Moon, A. D. Kohn, G. V. De Ferrari andA. Kaykas,WNT and beta-catenin signalling: diseases and therapies, Nat Rev Genet 5 (2004), 691-701.
75. P. J. Morin, A. B. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein and K. W. Kinzler, Activation of beta-cateninTcf signa ing in colon cancer by mutations in beta-catenin or APC, Science 275 (1997), 1787-1790.
76. R. T. Burks, T. D. Kessis, K. R. Cho and L. Hedrick, Microsatellite instability in endometrial carcinoma, Oncogene 9 (1994), 1163-1166.
77. B. D. Duggan, J. C. Felix, L. I. Muderspach, D. Tourgeman, J. Zheng and D. Shibata, Microsatellite instability in sporadic endometrial carcinoma, J Natl Cancer Inst 86 (1994), 1216-1221.
78. G. L. Mutter, K. A. Boynton, W. C. Faquin, R. E. Ruiz and A. S. Jovanovic, Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer, Cancer Res 56 (1996), 4483-4486.
79. J. I. Risinger, A. Berchuck, M. F. Kohler, P. Watson, H. T. Lynch and J. Boyd, Genetic instability of microsatellites in endometrial carcinoma, Cancer Res 53 (1993), 5100-5103.
80. G. L. Mutter, M. C. Lin, J. T. Fitzgerald, J. B. Kum, J. P. Baak, J. A. Lees, L. P. Weng and C. Eng, Altered PTENexpression as a diagnostic marker for the earliest endometrial precancers, J Natl Cancer Inst 92 (2000), 924-930.
81. V. Stambolic, M. S. Tsao, D. Macpherson, A. Suzuki, W. B. Chapman and T. W. Mak, High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice, Cancer Res 60 (2000), 3605-3611.
82. S. F. Lax, B. Kendall, H. Tashiro, R. J. Slebos and L. Hedrick, The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways, Cancer 88 (2000), 814-824.
83. H. Sasaki, H. Nishii, H. Takahashi, A. Tada, M. Furusato, Y. Terashima, G. P. Siegal, S. L. Parker, M. F. Kohler, A. Berchuck and et al. , Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma, Cancer Res 53 (1993), 1906-1910.
84. E. M. Swisher, S. Peiffer-Schneider, D. G. Mutch, T. J. Herzog, J. S. Rader, A. Elbendary and P. J. Goodfellow, Differences in patterns of TP53 and KRAS2mutations in a large series of endometrial carcinomas with or without microsatellite instability, Cancer 85 (1999), 119-126.
85. L. Mirabelli-Primdahl, R. Gryfe, H. Kim, A. Millar, C. Luceri, D. Dale, E. Holowaty, B. Bapat, S. Gallinger and M. Redston, Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway, Cancer Res 59 (1999), 3346-3351.
86. J. Palacios and C. Gamallo, Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas, Cancer Res 58 (1998), 1344-1347.
87. B. Rubinfeld, I. Albert, E. Porfiri, C. Fiol, S. Munemitsu and P. Polakis, Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly, Science 272 (1996), 1023-1026.
88. L. K. Su, B. Vogelstein and K. W. Kinzler, Association of the APC tumor suppressor protein with catenins, Science 262 (1993), 1734-1737.
89. J. M. Pijnenborg, L. van de Broek, G. C. Dam de Veen, G. M. Roemen, J. de Haan, M. van Engeland, J. W. Voncken and P. G. Groothuis, TP53 overexpression in recurrent endometrial carcinoma, Gynecol Oncol 100 (2006), 397-404.
90. M. J. Schmitz, D. T. Hendricks, J. Farley, R. R. Taylor, J. Geradts, G. S. Rose and M. J. Birrer, p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma, Gynecol Oncol 77 (2000), 439-445.
91. R. A. Soslow, P. U. Shen, M. H. Chung andC. Isacson, Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma, Int J Gynecol Pathol 17 (1998), 129-134.
92. P. J. Goodfellow, B. M. Buttin, T. J. Herzog, J. S. Rader, R. K. Gibb, E. Swisher, K. Look, K. C. Walls, M. Y. Fan and D. G. Mutch, Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers, Proc Natl Acad Sci U S A 100 (2003), 5908-5913.
93. M. E. Sherman, M. E. Bur and R. J. Kurman, p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis, Hum Pathol 26 (1995), 1268-1274.
94. S. F. Lax, E. S. Pizer, B. M. Ronnett and R. J. Kurman, Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression, Hum Pathol 29 (1998), 551-558.
95. D. Abramovich, M. Markman, A. Kennedy, K. Webster and J. Belinson, Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma, J Cancer Res Clin Oncol 125 (1999), 697-698.
96. G. E. Konecny, L. Santos, B. Winterhoff, M. Hatmal, G. L. Keeney, A. Mariani, M. Jones, C. Neuper, B. Thomas, L. Muderspach, D. Riehle, H. J. Wang, S. Dowdy, K. C. Podratz and M. F. Press, HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer, Br J Cancer 100 (2009), 89-95.
97. D. J. Hetzel, T. O. Wilson, G. L. Keeney, P. C. Roche, S. S. Cha andK. C. Podratz, HER-2/neu expression: amajor prognostic factor in endometrial cancer, Gynecol Oncol 47 (1992), 179-185.
98. C. Morrison, V. Zanagnolo, N. Ramirez, D. E. Cohn, N. Kelbick, L. Copeland, G. L. Maxwell and J. M. Fowler, HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients, J Clin Oncol 24 (2006), 2376-2385.
99. L. Ries, M. Eisner, C. Kosary, B. Hankey, B. Miller, L. Clegg, A. Mariotto, E. Feuer and B. Edwards, SEER Cancer Statistics Review (2005), 1975-2002.
100. J. P. Baak, G. L. Mutter, S. Robboy, P. J. van Diest, A. M. Uyterlinde, A. Orbo, J. Palazzo, B. Fiane, K. Lovslett, C. Burger, F. Voorhorst and R. H. Verheijen, The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 WorldHealthOrganization classification system, Cancer 103 (2005), 2304-2312.
101. G. L. Mutter, J. P. Baak, C. P. Crum and R. M. Richart, A. Ferenczy and W. C. Faquin, Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry, J Pathol 190 (2000), 462-469.
102. M. Esteller, L. Catasus, X. Matias-Guiu, G. L. Mutter, J. Prat, S. B. Baylin and J. G. Herman, hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis, Am J Pathol 155 (1999), 1767-1772.
103. G. L. Mutter, R. J. Zaino, J. P. Baak, R. C. Bentley and S. J. Robboy, Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia, Int J Gynecol Pathol 26 (2007), 103-114.
104. M. Lin, K. A. Burkholder, A. N. Viswanathan, D. Neuberg and G. L. Mutter, Involution of latent endometrial precancersby horm nal and non hormonal mechanisms, Cancer 115 (2009), 2111-2118.
105. D. A. Grimes and K. E. Economy, Primary prevention of gynecologic cancers, Am J Obstet Gynecol 172 (1995), 227-235.
106. E. Weiderpass, H. O. Adami, J. A. Baron, C. Magnusson, A. Lindgren and I. Persson, Use of oral contraceptives and endometrial cancer risk (Sweden), Cancer Causes Control 10 (1999), 277-284.
107. M. E. Sherman, P. Bitterman, N. B. Rosenshein, G. Delgado and R. J. Kurman, Uterine serous carcinoma, A morphologically diverse neoplasm with unifying clinicopathologic features, Am J Surg Pathol 16 (1992), 600-610.
108. S. Silverberg, G. Mutter, R. Kurman, R. Kubik-Huch, F. Nogales and F. Tavassoli, Tumors of the uterine corpus: epithelial tumors and related lesions, in: WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs, F. Tavassoli andM. Stratton, Editors IARC Press Lyon France (2003), pp. 221-232.
109. W. Zheng, S. X. Liang, H. Yu, T. Rutherford, S. K. Chambers and P. E. Schwartz, Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features, Int J Surg Pathol 12 (2004), 207-223.
110. R. A. Ambros, M. E. Sherman, C. M. Zahn, P. Bitterman and R. J. Kurman, Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation, Hum Pathol 26 (1995), 1260-1267.
111. W. Zheng, R. Khurana, S. Farahmand, Y. Wang, Z. F. Zhang and J. C. Felix, p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma, Am J Surg Pathol 22 (1998), 1463-1473.
112. D. T. Wheeler, K. A. Bell, R. J. Kurman and M. E. Sherman, Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation, Am J Surg Pathol 24 (2000), 797-806.
113. S. X. Liang, S. K. Chambers, L. Cheng, S. Zhang, Y. Zhou and W. Zheng, Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features, Int J Surg Pathol 12 (2004), 319-331.
114. N. L. Sieben, P. Macropoulos, G. M. Roemen, S. M. Kolkman- Uljee, G. Jan Fleuren, R. Houmadi, T. Diss, B. Warren, M. Al Adnani, A. P. De Goeij, T. Krausz and A. M. Flanagan, In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours, J Pathol 202 (2004), 336-340.
115. G. Singer, R. Oldt, 3rd, Y. Cohen, B. G. Wang, D. Sidransky, R. J. Kurman and M. Shih Ie, Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma, J Natl Cancer Inst 95 (2003), 484-486.
116. I. Meinhold-Heerlein, D. Bauerschlag, F. Hilpert, P. Dimitrov, L. M. Sapinoso, M. Orlowska-Volk, T. Bauknecht, T. W. Park, W. Jonat, A. Jacobsen, J. Sehouli, J. Luttges, M. Krajewski, S. Krajewski, J. C. Reed, N. Arnold and G. M. Hampton, Molecular and prognostic distinction between serous ovarian carcinomas of varying grade andmalignant potential, Oncogene 24 (2005), 1053-1065.
117. A. Staebler, K. Heselmeyer-Haddad, K. Bell, M. Riopel, E. Perlman, T. Ried and R. J. Kurman, Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas, Hum Pathol 33 (2002), 47-59.
118. H. J. Allen, R. A. DiCioccio, P. Hohmann, M. S. Piver and H. Tworek, Microsatellite instability in ovarian and other pelvic carcinomas, Cancer Genet Cytogenet 117 (2000), 163-166.
119. L. M. Kmet, L. S. Cook and A. M. Magliocco, A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors, Cancer 97 (2003), 389-404.
120. J. S. Ross, F. Yang, B. V. Kallakury, C. E. Sheehan, R. A. Ambros and P. J. Muraca, HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary, Am J Clin Pathol 111 (1999), 311-316.
121. A. M. Afify, B. A. Werness and H. F. Mark, HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma, Exp Mol Pathol 66 (1999), 163-169.
122. K. Nakayama, N. Nakayama, R. J. Kurman, L. Cope, G. Pohl, Y. Samuels, V. E. Velculescu, T. L. Wang and M. Shih Ie, Sequence Mutations and Amplification of PIK3CA and AKT2 Genes in Purified Ovarian Serous Neoplasms, Cancer Biol Ther 5 (2006), 779-785.
123. K. Nakayama, N. Nakayama, N. Jinawath, R. Salani, R. J. Kurman, M. Shih Ie and T. L. Wang, Amplicon profiles in ovarian serous carcinomas, Int J Cancer 120 (2007), 2613-2617.
124. G. G. Garzetti, A. Ciavattini, G. Goteri, M. De Nictolis, D. Stramazzotti, G. Lucarini and G. Biagini, Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance, Gynecol Oncol 56 (1995), 169-174.
125. L. Shih and R. J. Kurman, Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges, Clin Cancer Res 11 (2005), 7273-7279.
126. D. A. Bell and R. E. Scully, Early de novo ovarian carcinoma, Cancer 73 (1994), 1859-1864.
127. C. P. Crum, R. Drapkin, A. Miron, T. A. Ince, M. Muto, D. W. Kindelberger and Y. Lee, The distal fallopian tube: a new model for pelvic serous carcinogenesis, Curr Opin Obstet Gynecol 19 (2007), 3-9.
128. E. A. Jarboe, A. K. Folkins, R. Drapkin, T. A. Ince, E. S. Agoston and C. P. Crum, Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective, Histopathology 53 (2008), 127-138.
129. M. L. Gemignani, A. C. Schlaerth, F. Bogomolniy, R. R. Barakat, O. Lin, R. Soslow, E. Venkatraman and J. Boyd, Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma, Gynecol Oncol 90 (2003), 378-381.
130. Y. Ichikawa, M. Nishida, H. Suzuki, S. Yoshida, H. Tsunoda, T. Kubo, K. Uchida and M. Miwa, Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors, Cancer Res 54 (1994), 33-35.
131. S. C. Mok, D. A. Bell, R. C. Knapp, P. M. Fishbaugh, W. R. Welch, M. G. Muto, R. S. Berkowitz and S. W. Tsao,Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy, Cancer Res 53 (1993), 1489-1492.
132. M. Cuatrecasas, A. Villanueva, X. Matias-Guiu and J. Prat, K-ras mutations inmucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases, Cancer 79 (1997), 1581-1586.
133. M. Mandai, I. Konishi, H. Kuroda, T. Komatsu, S. Yamamoto, K. Nanbu, K. Matsushita, M. Fukumoto, H. Yamabe and T. Mori, Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology, Hum Pathol 29 (1998), 34-40.
134. B. Litkouhi, B. Litkouhi, E. Fleming, W. R. Welch, R. S. Berkowitz, M. J. Birrer and S. C. Mok, Overexpression ofCEACAM6in bo derline and invasivemucinous ovarian neoplasms, Gynecol Oncol 109 (2008), 234-239.
135. Y. C. Shih, J. Kerr, T. G. Hurst, S. K. Khoo, B. G. Ward and G. Chenevix-Trench, No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasms, Gynecol Oncol 69 (1998), 210-213.
136. S. Jordan, A. Green and P. Webb, Benign Epithelial Ovarian Tumours-cancer Precursors or Markers for Ovarian Cancer Risk? Cancer Causes Control 17 (2006), 623-632.
137. R. E. Scully, Early denovo ovarian cancer and cancer developing in benign ovarian lesions, International Journal of Gynaecology and Obstetrics 49 (1995), S9-S15.
138. A. P. Garrett, K. R. Lee, C. R. Colitti, M. G. Muto, R. S. Berkowitz and S. C. Mok, k-ras mutation may be an early event in mucinous ovarian tumorigenesis, Int J Gynecol Pathol 20 (2001), 244-251.
139. L. Dubeau, The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 72 (1999), 437-442.
140. M. Fujita, T. Enomoto, K. Yoshino, T. Nomura, G. S. Buzard, M. Inoue and Y. Okudaira, Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer, Int J Cancer 64 (1995), 361-366.
141. E. Gras, L. Catasus, R. Arguelles, G. Moreno-Bueno, J. Palacios, C. Gamallo, X. Matias-Guiu and J. Prat, Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors, Cancer 92 (2001), 2829-2836.
142. K. Obata,, S. J. Morland, R. H. Watson, A. Hitchcock, G. Chenevix-Trench, E. J. Thomas and I. G. Campbell, Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors, Cancer Res 58 (1998), 2095-2097.
143. M. Cuatrecasas, N. Erill, E. Musulen, I. Costa, X. Matias- Guiu and J. Prat, K-ras mutations in nonmucinous ovarian epithelial tumors: amolecular analysis and clinicopathologic study of 144 patients, Cancer 82 (1998), 1088-1095.
144. D. S. Tan and S. Kaye, Ovarian clear cell adenocarcinoma: a continuing enigma, J Clin Pathol 60 (2007), 355-360.
145. 145] N. Sato, H. Tsunoda, M. Nishida, Y. Morishita, Y. Takimoto, T. Kubo and M. Noguchi, Loss of heterozygosity on 10q23. 3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary, Cancer Res 60 (2000), 7052-7056.
146. Y. Hashiguchi, H. Tsuda, T. Inoue, R. S. Berkowitz and S. C. Mok, PTEN expression in clear cell adenocarcinoma of the ovary, Gynecol Oncol 101 (2006), 71-75.
147. K. M. Francis-Thickpenny, D. M. Richardson, C. C. van Ee, D. R. Love, I. M. Winship, B. C. Baguley, G. Chenevix-Trench and A. N. Shelling, Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma, Br J Cancer 85 (2001), 687-691.
148. A. Tsuchiya, M. Sakamoto, J. Yasuda, M. Chuma, T. Ohta, M. Ohki, T. Yasugi, Y. Taketani and S. Hirohashi, Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma, Am J Pathol 163 (2003), 2503-2512.
149. N. Kato, S. Sasou and T. Motoyama, Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary, Mod Pathol 19 (2006), 83-89.
150. R. B. Ness, Endometriosis and ovarian cancer: thoughts on shared pathophysiology, Am J Obstet Gynecol 189 (2003), 280-294.
151. E. Somigliana, P. Vigano, F. Parazzini, S. Stoppelli, E. Giambattista and P. Vercellini, Association between endometriosis and cancer: A comprehensive review and a critical analysis of clinical and epidemiological evidence, Gynecol Oncol 101 (2006), 331-341.
152. E. J. Thomas and I. G. Campbell, Molecular genetic defects in endometriosis, Gynecol Obstet Invest 50 Suppl 1 (2000), 44-50.
153. D. M. Dinulescu, T. A. Ince, B. J. Quade, S. A. Shafer, D. Crowley and T. Jacks, Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer, Nat Med 11 (2005), 63-70.
154. Y. Wu, G. Halverson, Z. Basir, E. Strawn, P. Yan and S. W. Guo, Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis, Am J Obstet Gynecol 193 (2005), 371-380.
155. W. Zheng, N. Li, J. Wang, E. C. Ulukus, M. Ulukus, A. Arici and S. X. Liang, Initial endometriosis showing direct morphologic evidence of metaplasia in the pathogenesis of ovarian endometriosis, Int J Gynecol Pathol 24 (2005), 164-172.
156. M. J. Callahan, C. P. Crum, F. Medeiros, D. W. Kindelberger, J. A. Elvin, J. E. Garber, C. M. Feltmate, R. S. Berkowitz and M. G. Muto, Primary fallopian tube malignancies in BRCApositive women undergoing surgery for ovarian cancer risk reduction, J Clin Oncol 25 (2007), 3985-3990.
157. Y. Lee, F. Medeiros, D. Kindelberger, M. J. Callahan, M. G. Muto and C. P. Crum, Advances in the recognition of tubal intraepithelial carcinoma applications to cancer screeningand the pathogenesis of ovarian cancer, Adv Anat Pathol 13 (2006), 1-7.
158. R. T. Marquez, K. A. Baggerly, A. P. Patterson, J. Liu, R. Broaddus,M. Frumovitz, E. N. Atkinson, D. I. Smith, L. Hartmann, D. Fishman, A. Berchuck, R. Whitaker, D. M. Gershenson, G. B. Mills, R. C. Bast, Jr. and K. H. Lu, Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon, Clin Cancer Res 11 (2005), 6116-6126.
159. S. J. Jordan, A. C. Green, D. C. Whiteman, S. P. Moore, C. J. Bain, D. M. Gertig and P. M. Webb, Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis, Int J Cancer 122 (2008), 1598-1603.
160. K. K. Zorn, T. Bonome, L. Gangi, G. V. Chandramouli, C. S. Awtrey, G. J. Gardner, J. C. Barrett, J. Boyd and M. J. Birrer, Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer, Clin Cancer Res 11 (2005), 6422-6430.
161. J. Ferlay, F. Bray, P. Pisani and D. Parkin (2004) Globocan 2002. 2009, Cancer Incidence, Mortality and Prevalence Worldwide
162. L. A. Brinton, M. L. Berman, R. Mortel, L. B. Twiggs, R. J. Barrett, G.
163. S. J. Jordan, P. M. Webb and A. C. Green, Height, age atmenarche, and risk of epithelial ovarian cancer, Cancer Epidemiol Biomarkers Prev 14 (2005), 2045-2048.
164. L. Titus-Ernstoff, K. Perez, D. W. Cramer, B. L. Harlow, J. A. Baron and E. R. Greenberg, Menstrual and reproductive factors in relation to ovarian cancer risk, Br J Cancer 84 (2001), 714-721.
165. B. E. Henderson, J. T. Casagrande, M. C. Pike, T. Mack, I. Rosario and A. Duke, The epidemiology of endometrial cancer in young women, Br J Cancer 47 (1983), 749-756.
166. B. E. Henderson, R. Ross and L. Bernstein, Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture, Cancer Res 48 (1988), 246-253.
167. A. S. Whittemore, R. Harris and J. Itnyre, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group, Am J Epidemiol 136 (1992), 1184-1203.
168. G. Kvale, I. Heuch and G. E. Eide, A prospective study of reproductive factors and breast cancer. I. Parity, Am J Epidemiol 126 (1987), 831-841.
169. M. Lambe, J. Wuu, E. Weiderpass and C. C. Hsieh, Childbearing at older age and endometrial cancer risk (Sweden), Cancer Causes Control 10 (1999), 43-49.
170. P. A. Newcomb and A. Trentham-Dietz, Breast feeding practices in relation to endometrial cancer risk, USA, Cancer Causes Control 11 (2000), 663-667.
171. C. Okamur, Y. Tsubono, K. Ito, H. Niikura, T. Takano, S. Nagase, K. Yoshinaga, Y. Terada, T. Murakami, S. Sato, D. Aoki, T. Jobo, K. Okamura and N. Yaegashi, Lactation and risk of endometrial cancer in Japan: a case-control study, Tohoku J Exp Med 208 (2006), 109-115.
172. K. A. Rosenblatt and D. B. Thomas, Prolonged lactation and endometrial cancer. WHO Collaborative Study of Neoplasia and Steroid Contraceptives, Int J Epidemiol 24 (1995), 499-503.
173. E. Salazar-Martinez, E. C. Lazcano-Ponce, G. Gonzalez Lira- Lira, P. Escudero-De los Rios, J. Salmeron-Castro and M. Hernandez-Avila, Reproductive factors of ovarian and endometrial cancer risk in a high fertility population inMexico, Cancer Res 59 (1999), 3658-3662.
174. V. Siskind, A. Green, C. Bain and D. Purdie, Breastfeeding, menopause, and epithelial ovarian cancer, Epidemiology 8 (1997), 188-191.
175. C. La Vecchia, Oral contraceptives and ovarian cancer: an update, 1998-2004, Eur J Cancer Prev 15 (2006), 117-124.
176. G. L. Maxwell, J. M. Schildkraut, B. Calingaert, J. I. Risinger, L. Dainty, P. A. Marchbanks, A. Berchuck, J. C. Barrett and G. C. Rodriguez, Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk, Gynecol Oncol 103 (2006), 535-540.
177. J. J. Schlesselman, Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis, Hum Reprod 12 (1997), 1851-1863.
178. S. G. Silverberg and E. L. Makowski, Endometrial carcinoma in young women taking oral contraceptive agents, Obstet Gynecol 46 (1975), 503-506.
179. J. T. Casagrande, E. W. Louie, M. C. Pike, S. Roy, R. K. Ross and B. E. Henderson, "Incessant ovulation" and ovarian cancer, Lancet 2 (1979), 170-173.
180. D. M. Purdie, C. J. Bain, V. Siskind, P. M. Webb and A. C. Green, Ovulation and risk of epithelial ovarian cancer, Int J Cancer 104 (2003), 228-232.
181. V. Beral, D. Bull and G. Reeves, Endometrial cancer and hormone-replacement therapy in the Million Women Study, Lancet 365 (2005), 1543-1551.
182. P. P. Garg, K. Kerlikowske, L. Subak and D. Grady, Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis, Obstet Gynecol 92 (1998), 472-479.
183. D. Grady, T. Gebretsadik, K. Kerlikowske, V. Ernster and D. Petitti, Hormone replacement therapy and endometrial cancer risk: ameta-analysis, Obstet Gynecol 85 (1995), 304-313.
184. C. Rodriguez, A. V. Patel, E. E. Calle, E. J. Jacob and M. J. Thun, Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women, Jama 285 (2001), 1460-1465.
185. J. E. Rossouw, G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, R. D. Jackson, S. A. Beresford, B. V. Howard, K. C. Johnson, J. M. Kotchen and J. Ockene, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, Jama 288 (2002), 321-333.
186. C. L. Pearce, K. Chung, M. C. Pike and A. H. Wu, Increased ovarian cancer risk associatedwithmenopausal estrogen therapy is reduced by adding a progestin, Cancer 115 (2009), 531-539.
187. H. Kuper, D. W. Cramer and L. Titus-Ernstoff, Risk of ovarian cancer in the United States in relation to anthropometric measures: does the association depend on menopausal status? Cancer Causes Control 13 (2002), 455-463.
188. E. Weiderpass, I. Persson, H. O. Adami, C. Magnusson, A. Lindgren and J. A. Baron, Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden), Cancer Causes Control 11 (2000), 185-192.
189. H. D. Nelson, L. H. Huffman, R. Fu and E. L. Harris, Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U. S. Preventive Services Task Force, Ann Intern Med 143 (2005), 362-379.
190. L. A. Brinton, R. J. Barrett, M. L. Berman, R. Mortel, L. B. Twiggs and G. D. Wilbanks, Cigarette smoking and the risk of endometrial cancer, Am J Epidemiol 137 (1993), 281-291.
191. S. Y. Pan, A. M. Ugnat, Y. Mao, S. W. Wen and K. C. Johnson, Association of cigarette smoking with the risk of ovarian cancer, Int J Cancer 111 (2004), 124-130.
192. M. A. Rossing, K. L. Cushing-Haugen, K. G. Wicklund and N. S. Weiss, Cigarette smoking and risk of epithelial ovarian cancer, Cancer Causes Control 19 (2008), 413-420.
193. Y. Zhang, P. F. Coogan, J. R. Palmer, B. L. Strom and L. Rosenberg, Cigarette smoking and increased risk of mucinous epithelial ovarian cancer, AmJ Epidemiol 159 (2004), 133-139.
194. N. Kreiger, M. Sloan, M. Cotterchio and P. Parsons, Surgical procedures associated with risk of ovarian cancer, Int J Epidemiol 26 (1997), 710-715.
195. D. W. Cramer, L. Titus-Ernstoff, J. R. McKolanis, W. R. Welch, A. F. Vitonis, R. S. Berkowitz and O. J. Finn, Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer, Cancer Epidemiol Biomarkers Prev 14 (2005), 1125-1131.
196. D. Hubacher and D. A. Grimes, Noncontraceptive health benefits of intrauterine devices: a systematic review, Obstet Gynecol Surv 57 (2002), 120-128.
197. E. Oliva, P. Clement and R. Young, Pathology of sarcomas andmixedmullerian tumors of the uterine corpus, in: Uterine Cancer, A. Fuller, M. Seiden and R. Young, eds, BC Decker Inc, 2004.
198. R. Young and P. Clement, Pathology of Endometrial Carcinoma, in: Uterine Cancer, A. Fuller, M. Seiden and R. Young, eds, BC Decker Inc, 2004.
199. L. Ries, D. Melbert,M. Krapcho, D. Stinchcomb, N. Howlader, M. Horner, A. Mariotto, E. Feuer, S. Altedruse, D. Lewis, L. Clegg, M. Eisner, M. Reichman and B. Edwards, SEER Cancer Statistics Review (2008), 1975-2005.